Evidence map›Paper›PMID 37965463›Full record

ArticleFrontiers in oncology2023

PDGF, NGF, and EGF as main contributors to tumorigenesis in high-risk retinoblastoma.

Karim Al-Ghazzawi, Michael Wessolly, Sami Dalbah, Petra Ketteler, Tobias Kiefer, Nikolaos Bechrakis, Jabbarli Leyla, Saskia Ting, Eva Biewald, Fabian D Mairinger

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Karim Al-GhazzawiDepartment of Ophthalmology, University Hospital Essen, Essen, Germany.
Michael WessollyDepartment of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Sami DalbahDepartment of Ophthalmology, University Hospital Essen, Essen, Germany.
Petra KettelerDepartment of Pediatric Hematology and Oncology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Tobias KieferDepartment of Ophthalmology, University Hospital Essen, Essen, Germany.
Nikolaos BechrakisDepartment of Ophthalmology, University Hospital Essen, Essen, Germany.
Jabbarli LeylaDepartment of Ophthalmology, University Hospital Essen, Essen, Germany.
Saskia TingInstitute of Pathology Nordhessen, Kassel, Germany.
Eva BiewaldDepartment of Ophthalmology, University Hospital Essen, Essen, Germany.
Fabian D MairingerDepartment of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Essen University Hospital · DEUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinoblastoma (RB) is the most common form of eye cancer experienced in childhood. Its aggressive malignancy is associated with excellent survival rates in high-income countries; however, the prognosis in third-world countries is less favorable. Early diagnosis can maximize the patient's visual outcomes and their survival rate. Therapy should be conducted in highly specialized treatment centers. Intravenous chemotherapy (IVC) in bilaterally affected children currently forms the majority of therapy. Local destructive procedures and local chemotherapies such as intra-arterial chemotherapy (IAC) or intravitreal chemotherapy can be taken into consideration depending on the extent and size of the tumor. Nonetheless, children and parents remain under constant stress, revisiting doctors for medical treatment and fearing vision loss and even enucleation of the eye. Adequate molecular patient stratification to improve targeted therapy is still lacking. This retrospective study analyzed formalin-fixed paraffin-embedded specimens from a cohort of 21 RB samples. A total of 11 of those samples showed undifferentiated retinoblastoma (URB) histopathological risk features, and the other 10 showed differentiated retinoblastoma (DRB) histopathological grading. RNA from all samples was isolated and analyzed via digital gene expression patterns. Conductors of cell survival and DNA repair were dominant in the DRB samples. In contrast, the agents responsible for cell-cycle progression and apoptosis were overexpressed in URB samples. Our work reveals the importance of molecular mechanisms within the immune system subjected to histologic subtypes of RB, providing more detailed background on their genetic behavior. This is of great interest for therapeutic strategies, such as targeted immune- and gene-based therapies, for retinoblastoma.

Indexed as

biomarkersgrowth factors (angiogenesis factors)MAPK/ERK2 pathway 1PDGF = platelet-derived growth factorpediatric cancer and oncologyretinoblastomaretinoblastoma - epigeneticstargeted therapy

Identifiers

PMID37965463
PMCPMC10642836
OpenAlexW4388023212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.